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Abstract:  Naturally  occurring  cucurbitacins  have  been  shown  to  have  anticancer, 
antimicrobial and anti-inflammatory activities. In this study, we determined the effects of 
cucurbitacin B extracted from the Thai herb Trichosanthes cucumerina L. on telomerase 
regulation in three human breast cancer cell lines (T47D, SKBR-3, and MCF-7) and a 
mammary epithelium cell line (HBL-100). Cell viability after treatment with cucurbitacin 
B, which is an active ingredient of this herb, was assessed. Telomeric Repeat Amplification 
Protocol  (TRAP)  assays  and  RT-PCR  (qualitative  and  realtime)  were  performed  to 
investigate  activity  of  telomerase  as  well  as  expression  of  human  telomerase  reverse 
transcriptase  (hTERT)  and  c-Myc.  The  c-Myc  protein  level  was  also  determined  in  
SKBR-3 and HBL-100 cells. Our results show that the cucurbitacin B inhibits growth and 
telomerase activity in the three breast cancer cell lines and exerts an obvious inhibitory 
effect in the estrogen receptor (ER)-negative breast cancer SKBR-3 cells. The expression of 
hTERT and c-Myc were also inhibited by cucurbitacin B, In addition, a clear reduction of 
c-Myc protein was observed after treatment in SKBR-3 cells even with a concentration of 
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cucurbitacin  B  that  was  ten-times  lower  compared  to  the  concentration  used  for  
HBL-100. Our findings imply that cucurbitacin B exerts an anticancer effect by inhibiting 
telomerase  via  down  regulating  both  the  hTERT  and  c-Myc  expression  in  breast  
cancer cells. 
Keywords: cucurbitacin B; telomerase; hTERT; c-Myc; breast cancer; estrogen receptor  
 
1. Introduction  
The rising incidence of breast cancer makes this disease a major public health problem
 and breast 
cancer is the most common female cancer worldwide [1,2]. Telomerase, the enzyme responsible for 
maintaining telomeres, is highly expressed in over 90% of breast cancer tumors, but the expression is 
low in normal breast tissue [3,4].
 Telomeric TTAGGG tandem repeats at the ends of chromosomes 
protect the chromosomes from end-to-end fusion, rearrangement and translocation [5,6]. In normal 
somatic cells with low telomerase levels, DNA polymerase cannot completely replicate the 5 end of 
the lagging strand, leading to telomere shortening with each cell division. This telomere shortening 
triggers the cell to undergo replicative senescence, cell cycle arrest and DNA damage signaling [7,8].
 
Telomerase consists of two core subunits required for its activity: the human telomerase RNA template 
(hTERC)  and  the  catalytic  subunit  of  human  telomerase  reverse  transcriptase  (hTERT)  [9,10]. 
Telomerase  plays  a  role  in  cell  proliferation  as  a  protective  mechanism  against  end-replication 
problems by adding TTAGGG repeats to the telomeres [11]. Telomerase is highly active only in germ 
cells and in tissue stem cells. Increased expression of telomerase is strongly associated with neoplastic 
growth and the expression of telomerase in cancer cells may be a necessary step for tumor progression. 
Therefore, the development of agents having activity against telomerase may be a productive approach 
to develop novel breast cancer therapies [12–14]. Chemotherapeutic drugs are quite toxic for patients 
and often result in drug resistance after a certain period. The use of alternative therapies is widespread 
in all regions of the developing world, and is rapidly growing in industrialized countries [15]. Natural 
cucurbitans are highly oxygenated, tetracyclic triterpenes containing the cucurbitane nucleus skeleton 
and  are  predominantly  found  in  plants  of  the  family  cucurbitaceae,  members  of  which  have  long  
been used in oriental medicines. Cucurbitacin B and dihydrocucurbitacin B extracted from the Thai 
herb  Trichosanthes  cucumerina  L.  have  been  shown  to  have  anticancer,  antimicrobial  and  
anti-inflammatory activities [16,17] and the structures of these purified forms have been elucidated 
using  NMR  spectroscopy  [18].  A  previous  report  has  shown  that  cucurbitacin  B  and 
dihydrocucurbitacin  B  can  inhibit  the  growth  of  breast  cancer  cell  lines  [19],  but  the  molecular 
mechanism of this growth inhibition remains unclear. Therefore, in the report herein, we addressed the 
effects of cucurbitacin B on telomerase and associated genes in human breast cancer cell lines. Our 
findings strongly suggest the potential anti-breast cancer effect of cucurbitacin B.  Int. J. Mol. Sci. 2010, 11                       
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2. Results and Discussion  
2.1. Effect of Cucurbitacin B on the Viability of Human Breast Cancer Cells 
To investigate the effects of cucurbitacin B on human breast cancer cells, IC50 values for three 
extracts of T. cucumerina L were determined on breast cancer cell lines. The extracts used included a 
100% pure cucurbitacin B and a purified cucurbitacin B compound containing cucurbitacin B (major) 
and dihydrocucurbitacin B in 8:1 molar ratio. All were prepared as described elsewhere [19]. IC50 
values  of these purified extracts  were also  compared with  the spray-dried crude extract. SKBR-3, 
MCF-7, T47D and HBL-100 cells were incubated with concentrations of the three testing extracts, 
ranging between 1 and 100 µg/mL and assessed for cell viability using the MTT assay at 48 h post 
incubation.  All  three  extracts  showed  a  significant  growth  inhibitory  effect  against  SKBR-3  and  
HBL-100 cells, but less effect against MCF-7 and T-47D cells (Table 1 and Figure 1), suggesting that 
estrogen receptor (ER) negative cells are more sensitive to the action of these extracts. 
Given  that  very  similar,  albeit  only  slightly  lower  inhibitory  effects  were  observed  with  the 
cucurbitacin B compound (containing both cucurbitacin B and dihydrocucurbitacin B) as compared 
with purified cucurbitacin B, further experiments were performed to investigate the mechanism of 
action with the cucurbitacin B compound. 
Table 1. The half maximal inhibitory concentration (IC50) of three cucurbitacins extracted 
from T. cucumerina L. (Spray dried, cucurbitacin B major compound and pure cucurbitacin 
B) in breast cancer cell lines. 
Cells 
IC50 (µ g/mL) 
(Spray Dried) 
IC50 (µ g/mL) 
(CuB 
Compound) 
IC50 (µ g/mL)  
(Pure CuB) 
Cell’s Estrogen 
Receptor (ER) 
status 
SKBR3-3  <10  4.6  3.29  Neg 
HBL-100  73.7  55.4  32.77  Neg 
MCF-7  >100  88.75  63.07  Pos 
T47D  >100  >100  88.4  Pos 
 
To confirm the loss of cell viability observed in cells incubated with the cucurbitacin B, all four cell 
lines were incubated with the extract at the calculated IC50 values as indicated in Table 1 for 48 h, in 
parallel  with  the  control  (untreated)  cells.  Examination  of  cultures  by  phase  contrast  microscopy 
showed morphological changes, including cell shrinkage and membrane blebbing, after treatment with 
the extract. This observation is consistent with the induction of apoptosis in the treated cells (Figure 2) 
and supports the loss of cell viability as documented in the MTT assay.  Int. J. Mol. Sci. 2010, 11                       
 
 
5326 
Figure 1. Effect of cucurbitacin B on the growth of human breast cancer cells. SKBR-3, 
MCF-7 and HBL-100 were treated with cucurbitacin B at final concentrations of 1, 10, 20, 
40,  60,  80  and  100  µg/mL.  Cell  viability  was  determined  by  the  MTT  assay.  The 
percentage  of  viable  cells  was  calculated  by  defining  the  absorption  of  cells  without 
cucurbitacin  B  treatment  as  100%.  Results  are  the  average  from  three  independent 
experiments. 
 
Figure  2.  Morphological  changes  in  breast  cancer  cells  induced  by  cucurbitacin  B.  
Upper (1, 2, 3, and 4): Phase-contrast photomicrographs of untreated SKBR-3, HBL-100, 
MCF-7 and T47D cells. Lower (5, 6, 7, and 8): SKBR3, HBL-100, MCF-7 and T47D cells 
treated with cucurbitacin B at IC50 for 48 h.  
 
2.2. Effect of Cucurbitacin B on Telomerase Activity 
The effect of cucurbitacin B on telomerase activity was investigated. The human breast cancer cell 
lines were treated with cucurbitacin B at varying concentrations for 48 h. According to the markedly 
greater sensitivity of SKBR-3 cells to cucurbitacin B compound, the SKBR-3 cells were, therefore, Int. J. Mol. Sci. 2010, 11                       
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incubated at 10-fold lower concentrations than the other three cell lines. After incubation, telomerase 
activity was determined by the TRAP assay. As shown in Figure 3A, the band intensities of the 6 bp 
(TTAGGG) repeat length were reduced after incubation with cucurbitacin B in all cell lines tested, and 
the results are consistent with a dose dependent reduction of telomerase activity in the four cell lines. 
To  confirm  this,  relative  telomerase  activity  levels  were  determined  using  the  TRAPEZE-ELISA 
detection assay system, and a dose dependent reduction in telomerase levels was observed in all four 
cell  lines  (Figure  3B).  Both  the  assays  for  telomerase  activity  showed  a  greater  effect  of  the 
cucurbitacin B in the estrogen receptor negative cell lines (SKBR-3 and HBL-100) as compared to the 
estrogen  receptor  positive  cell  lines  (MCF-7  and  T47D),  consistent  with  the  results  from  the cell 
viability assays. Moreover, telomerase activity was obviously reduced in ER negative breast cancer 
SKBR-3 cells, even though concentrations of cucurbitacin B used for this cell type were 10-times less 
than the non-malignant mammary epithelium HBL-100. 
Figure  3.  Effect  of  cucurbitacin  B  on  telomerase  activity  in  breast  cancer  cells.  
(A) SKBR-3 cells were treated with cucurbitacin B at final concentrations of 0, 2, 4, 6, 8 
and 10 µg/mL while T47D, MCF-7 and HBL-100 cells were treated with cucurbitacin B at 
final concentrations of 0, 20, 40, 60, 80 and 100 µg/mL. Telomerase activity was examined 
by the TRAP assay and the decrease in telomerase activity was interpreted by means of 
reduced  intensities  of  bands  (stepwise  6  bp  (TTAGGG)  repetitive  ladder  bands).  
(B)  Relative  telomerase  activities  of  the  cells  after  cucurbitacin  B  treatment  were 
determined  by  the  TRAPEZE-ELISA  assay,  and  the  relative  telomerase  levels  are 
expressed as % relative activity. * P < 0.05 vs. control (untreated) group. 
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Figure 3. Cont. 
 
2.3. Effect of Cucurbitacin B on hTERT and c-Myc Gene Expression 
To further determine the mechanisms of telomerase inhibition by cucurbitacin B compound, the 
expression of two genes (hTERT and c-Myc) known to affect telomerase activity were analyzed by 
semi-quantitative  and  quantitative  realtime  RT-PCR.  For  semi-quantitative  RT-PCR,  the  cell  lines 
were incubated with cucurbitacin B at concentrations of 0, 20, 40, 60 and 80 g/mL (T47D, MCF-7 
and HBL-100) or 0, 2, 4, 6, 8 and 10 g/mL (SKBR-3) for 48 h and each experiment was undertaken in 
triplicate. Results, after normalization against -actin, are consistent with a dose dependent reduction 
of  both  hTERT  and  c-Myc  transcripts  in  all  four  cell  lines.  Again,  SKBR-3  shows  the  greatest 
reduction of hTERT and c-Myc expression after cucurbitacin B treatment (Figure 4). 
Realtime RT-PCR was undertaken to quantitate levels of the transcripts. For each cell line, only two 
concentrations of cucurbitacin B were tested in parallel with untreated cells: 50 and 100 µg/mL (for 
T47D, MCF-7 and HBL-100) or 5 and 10 µg/mL (for SKBR-3), and incubations were performed for 
48 h as mentioned above. Results from the e RT-PCR (Figure 5(A)) confirm that cucurbitacin B from 
T. cucumerina L. inhibits gene expression of hTERT and c-Myc. Expression of hTERT and c-Myc in 
SKBR-3 cells was again reduced the most, even at the lower cucurbitacin B concentration of 5 to  
10 µg/mL. The expression of c-Myc was mildly reduced in the estrogen positive cell lines (T47D and 
MCF-7), in contrast to the hTERT expression, in which the obvious reduction was also seen in these 
cells. Reduced c-Myc protein level in SKBR-3 cells is shown in Figure 5(B). 
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Figure  4.  Expression.of  hTERT  and  c-Myc  by  RT-PCR.  T47D, HBL-100, MCF-7 and 
SKBR-3 cells were incubated for 48 h with the specified concentrations of cucurbitacin B 
and  RNA  was  extracted  for  RT-PCR.  Levels  of  hTERT  and  c-Myc  expression  were 
analyzed.  Bands  representing  hTERT  and  c-Myc  are  shown  (A)  and  the  quantitative 
intensities  of  each  band  after  normalization  with  -actin  (B).  *  P  <  0.05  vs.  control 
(untreated) group. 
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Figure 5.  Expression of hTERT and c-Myc. (A) T47D, HBL-100, MCF-7 and SKBR-3 
cells were incubated with the specified concentrations of cucurbitacin B for 48 h and the 
quantitative expression levels of hTERT and c-Myc were analyzed by realtime RT-PCR as 
described in the text. Results shown are the average of three independent experiments.  
(B) c-Myc protein expression. SKBR-3 and HBL-100 were treated with cucurbitacin B for 
24 h. The cell lysates were separated by SDS-PAGE and analyzed by Western blot. 
 
                   B 
 
2.4. Effect of Cucurbitacin B on Cell Cycle Progression 
Effect  of  cucurbitacin  B  on  cell  cycle  progression  in  ER  negative  SKBR3  and  HBL-100  were 
analyzed according to the principle of the cells’ DNA content in each phase of cell cycle. The cells 
were treated with cucurbitacin B for 24 h and DNA content was analyzed via flow cytometry. The 
experiment was performed in triplicate. Results shows that the treated cells were arrested at the G2/M 
phase of cell cycle with decreased cell population in G1 and S (Figure 6), suggesting that cucurbitacin 
B inhibits growth via blocking the cell division cycle at the G2/M phase. In addition, a three-fold 
increase in the cell population in subG0 fraction after low concentration treatment with cucurbitacin B 
was seen in SKBR-3 compared to untreated cells (10.3% vs. 3.4%), implying apoptotic induction in 
these cells.  Int. J. Mol. Sci. 2010, 11                       
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Figure 6. Effect of cucurbitacin B on the cell cycle in human breast cancer cells. SKBR3 
and HBL-100 cells were incubated with cucurbitacin B for 24 h. The distribution of cell 
cycle stages was detected by propidium iodide (PI) staining. Results shown are the average 
of three independent experiments (A). Percent cells in each cell cycle phase represented as 
bar-graphs (B). Blockage at G2/M and apoptotic induction were observed in SKBR-3 after 
incubated with low concentration (5, 10 µg/mL) of cucurbitacin B.  
 
Over the last few years, telomerase has increasingly been seen as a viable target for cancer therapy, 
and as such there has been an increase in investigations seeking telomerase inhibitors as well as studies 
investigating  the  mode  of  action  of  these  inhibitors.  Inhibition  of  telomerase  leads  to  progressive 
telomeric shortening during successive cell cycles and subsequently results in growth arrest and cell 
death [20].  
Several reports have shown that telomerase activity can be inhibited by certain medicinal plants and 
extracts  thereof.  Medicinal  plants  are  those  in  which  some  part  of  the  plant  can  be  used  for  a 
therapeutic  purpose,  and  many  of  the  drugs  in  use  today  are  derived  from  medicinal  plants  [21]. 
Moreover,  many  studies  seek  to  find  new  drug  compounds  from  plants  used  in  traditional  
medicine [22].  Int. J. Mol. Sci. 2010, 11                       
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In 2005, Choi and colleagues reported that costunolide, a natural sesquiterpene compound derived 
from the bark of Magnolia sieboldii (a member of the Magnoliaceae family, which are commonly used 
in  oriental  traditional  medicine  [23]),  inhibited  the  growth  of  a  human  breast  cancer  cell  line  by 
reducing telomerase activity [24]. Similarly, Ramachandran and colleagues reported that curcumin, 
derived from the rhizomes of turmeric (Curcuma longa L.)—a plant with a long history of natural 
medicinal usage—can inhibit activity of telomerase by down-regulating hTERT expression in MCF-7 
breast cancer cells [25]. 
More recently, Mittal et al. reported the down-regulation of telomerase by (-)-epigallocatechin-3-
gallate (EGCG), a constituent of green tea, in MCF-7 cells, leading to suppressed viability of the cell 
and the induction of apoptosis [26]. Inhibition of telomerase is therefore an attractive approach for 
breast  cancer therapeutic goal,  and medicinal plants  seem to offer a wealth of potential candidate 
compounds. 
In  this  work,  we  report  the  antiproliferative  effect  of  a  cucurbitacin  extract  derived  from 
Trichosanthes cucumerina L. This plant is widely cultivated in Asia and the Indian sub-continent, 
where  it  has  a  long  history  of  medicinal  use  for  a  variety  of  disorders,  including  malignant  
growths [27,28]. The extract, consisting of cucurbitacin B and dihydrocucurbitacin B, was shown to 
have significant antiproliferative effect on the human breast cancer cell lines tested (T47D, MCF-7,  
SKBR-3) as well as HBL-100 cells. Cell cycle blockages at G2/M phase as well as a certain degree of 
apoptosis  were  seen  in  these  cell  lines,  especially  in  ER  negative  breast  cancer  SKBR-3  cells. 
Interestingly, the ER negative SKBR-3 cells were the most sensitive to cucurbitacin B when compared 
with the non-malignant HBL-100 cells and the other two breast cancer cells MCF-7 and T47D. As 
such, the different sensitivities to the cucurbitacin B compound seem to be directly related to estrogen 
receptor status, a finding that could be important for application of cucurbitacins to clinical practice. 
The cucurbitacin B reported here affected telomerase activity as well as the expression of genes 
associated with regulation of this enzyme in all cell types studied. Expression of the hTERT gene is 
directly  correlated  with  telomerase  activity  as  the  hTERT  protein  is  the  catalytic  rate-limiting 
determinant subunit of telomerase [29]. hTERT is a downstream target of c-Myc factor which binds to 
E-box  (CACGTG)  and  promotes  expression  of  the  hTERT  gene  [30].  Hence,  c-Myc  upregulates 
telomerase  by  enhancing  hTERT  expression  [31,32].  In  the  estrogen  positive  cell  lines  T47D  and  
MCF-7, however, the real time PCR showed some discordance between the reduction of expression of 
hTERT  and  c-Myc.  This  observation  suggests  that  cucurbitacin  B  might  exert its  antiproliferative 
effects in ER positive and ER negative breast cancer cells via different biological pathways. Support 
for this comes from studies in human breast cancer cells that have shown that estradiol primarily 
regulates c-Myc at the level of transcription in ER positive cells, but at a post-transcriptional level in 
ER negative cells [33]. In ER positive cells it is known that the estrogen receptor activates a number of 
cellular signal transduction pathways, including the ERK/MAPK pathway [34] and activation of this 
pathway  leads  to  the  translocation  of  activated MAP kinase to  the nucleus where it regulates  the 
expression of a number of transcription factors, including pertinently, c-Myc [35]. Hence, in the ER 
positive  cells,  it  is  possible  that  cucurbitacin  B  directly  modulates  either  the  estrogen  receptor  or 
subsequent  signaling  pathway  as  is  suggested  by  studies  that  shown  the  down  regulation  of  the 
JAK/STAT pathway by cucurbitacin in pancreatic cells [36]. In ER negative cells where c-Myc is Int. J. Mol. Sci. 2010, 11                       
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primarily controlled at the level of RNA stability [33], it is possible that cucurbitacin B reduces the half 
life of the RNA, leading to the loss of activation of hTERT. In both cases, cucurbitacin B could be 
acting  through  c-Myc,  directly  or  indirectly,  leading  to  the  reduction  of  telomerase  activity  and 
subsequent loss of cellular proliferation, as confirmed by the finding of cell cycle G2/M blockage after 
cucurbitacin B treatment. 
3. Experimental Section 
3.1. Plant Material and Cucurbitacin Purification 
Isolation  of  cucurbitacins  from  the  fruit  of  T.  cucurmerina  L.  was  undertaken  as  described 
previously [19]. In this study three extracts were used; a crude spray dried extract of the fruit juice of T. 
cucurmerina L, a cucurbitacin extract containing cucurbititacin B and dihydrocucurbitacin B in an 8:1 
molar ratio and purified cucurbititacin B [19]. Compounds and compound mixtures were dissolved in 
10% dimethylsulfoxide (DMSO) and diluted with DMEM/F12 medium (DMEM/F12, Gibco, Grand 
Island, NY, USA) to the desired concentrations prior to use. 
3.2. Cell Lines and Culture 
Human breast cancer cell lines T47D, SKBR-3, MCF-7 and normal mammary epithelium cell line 
HBL-100 were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) 
and were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM/F12, Gibco, Grand Island, NY, 
USA) supplemented with 10% Fetal Bovine Serum (FBS, Gibco, Grand Island, NY, USA), 1% of 
penicillin streptomycin (Gibco, Grand Island, NY, USA) at 37 ° C in a 5% CO2 incubator.  
3.3. Cell Viability 
Cell  viability  was  assessed  by  the  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  bromide 
(MTT) assay, which is based on the conversion of MTT to MTT-formazan by mitochondrial enzymes 
as described elsewhere [37]. Cells (1 ×  10
4 cells/well) were seeded into a 96-well plate and allowed to 
attach to the well overnight. Compounds were added to a specified final concentration (1, 10, 20, 40, 
60, 80 or 100 µg/mL) and cells incubated for a further 48 h. After incubation, 10 µL of 5 mg/mL  
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT, Millipore, Billerica, MA, USA) 
was added to the cells for 4 h at 37 ° C, followed by the addition of 100 µL isopropanol in 0.04 N HCl 
as the solubilizing agent. The absorbance at 570 nm was read using a microplate reader (Beckman 
coulter, Mississauga, ON, Canada) and the proportion of cell survival was calculated by dividing the 
average  absorbance  of  the  treated  cells  by  the  average  of  untreated  cells.  All  experiments  were 
performed in triplicate. 
3.4. Telomerase Assay 
Telomerase  activity  was  measured  by  the  PCR-based  Telomeric  Repeat  Amplification  Protocol 
(TRAP) assay
 [38,39], using the TRAPEZE ELISA Telomerase Detection Kit (Millipore, Billerica, 
MA, USA). The assay was performed following the manufacturer’s instructions. Briefly, 5 ×  10
5 cells Int. J. Mol. Sci. 2010, 11                       
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per  well  were  seeded  into  6-well  plates  and  incubated  with  cucurbitacin  isolates  at  the  specified 
concentration for 48 h. The cell pellets were then cooled on ice, lysed with CHAPS lysis buffer for 
30 min and centrifuged at 12,000 ×  g at 4 ° C for 20 min. The TRAP PCR reaction mixture contained 
1 µg of protein from each cell extraction, 1 µL of biotinylated TS primer, 1 µL of RP primer, 1 µL of 
internal control (K1 primer and TSK1 template), 2.5 mM dNTPs and 2 units Taq DNA polymerase. 
The PCR was performed for 33 cycles of 94 ° C for 30 sec, 55 ° C for 30 s, 72 ° C for 30 s and followed 
by a final extension at 72 ° C for 10 min. The PCR products were separated by electrophoresis through 
10% non-denaturing polyacrylamide gels to determine the degree of telomeric repeats and quantitated 
by ELISA to quantitatively determine telomerase activity. 
For ELISA, 5 µL of the PCR product was mixed with 100 µL of the blocking buffer into a well of a 
streptavidin-coaded microtiter plate and the samples were incubated at 37 ° C for 1 h. The blocking 
solution was completely removed and the well was rinsed 5 times with 250 µL of washing buffer. 
Afterthen,  100  µL  of  a  horseradish  peroxidase  conjugated  anti-dinitrophenyl  (DNP)  antibody  was 
added to  each well. The plate was incubated at room temperature for 30 min in  a dark chamber. 
Antibody solution was removed and the wells were rinsed 5 times with 250 µL of washing buffer 
before the addition of 100 µL Tetramethylbenzidine (TMB). Samples were incubated for 10 min at 
room  temperature  before  the  addition  of  100  µL  of  stop  solution.  Using  a  microplate  reader,  the 
amount  of  TRAP  product  was  determined by measuring the absorbance ratio at  450 and 690 nm 
(reference wavelength) within 30 min of stopping the reaction.  
3.5. RT-PCR  
Cells (5 ×  10
5 cells/well) were seeded into 6-well plates and treated with cucurbitacin at various 
concentrations  for  48  h.  Total  RNA  was  isolated  from  cell  pellets  using  the  RNeasy  Mini  Kit 
(QIAGEN,  Hilden,  Germany)  in  accordance  with  the  manufacturer’s  protocol.  Following  reverse 
transcription, cDNA was subsequently amplified by PCR with the primers shown in Table 2. The PCR 
conditions  were as  follows:  for hTERT and β-actin, 35 cycles of denaturation at  95  °C  for 30 s, 
annealing at 59.2 °C  for 30 s and extension at 72 °C  for 30 s. For c-Myc and β-actin, 30 cycles of 
denaturation at 95 º C for 30 sec, annealing at 59.8 °C  for 30 s and extension at 72 °C  for 30 s. The 
PCR  products  were  separated  by  electrophoresis  through  0.8%  agarose  gels  containing  ethidium 
bromide and the PCR products were viewed under UV illumination. The PCR product bands were 
analyzed using GeneSnap software (SYNGENE, Frederic, MD, USA) and relative intensities were 
calculated after normalization against β-actin.  
3.6. Realtime RT-PCR 
Cells (5 ×  10
5 cells/well) were seeded into 6-well plates and treated with cucurbitacins at various 
concentrations  for  48  h.  Total  RNA  was  isolated  from  cell  pellets  using  the  RNeasy  Mini  Kit 
(QIAGEN,  Hilden,  Germany)  in  accordance  with  the  manufacturer’s  protocol.  Following  reverse 
transcription, cDNA was subsequently amplified by realtime PCR, using SYBR-green in conjunction 
with the primers shown in Table 2. The PCR was analyzed using the iCycler iQ Multi-color Real-time 
PCR detection system (Bio-rad, Hercules, CA, USA). GAPDH was used as an internal control. All fold Int. J. Mol. Sci. 2010, 11                       
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differences  in  the  expression  are  expressed  relative  to  GAPDH  expression  in  the  corresponding 
samples.  
Table 2. The primer sequences for RT-PCR and Realtime PCR. 
Genes 
Primers  Fragment 
size (bp)  Forward   Reverse 
RT-PCR       
hTERT  5’-CGGAAGAGTGTCTGGAGCAA-3’  5’-GGATGAAGCGGAGTCTGGA-3’  145 
c-Myc  5’-AAGTCCTGCGCCTCGCAA-3’  5’-GCTGTGGCCTCCAGCAGA-3’  249 
-actin  5’-GCTCGTCGTCGACAACGGCT-3’  5’-CAAACATGATCTGGGTCATCTTCTC-3’  353 
Real-time 
PCR 
 
hTERT  5’-TCCACTCCCCACATAGGAATAGTC-3’  5’-TCCTTCTCAGGGTCTCCACCT-3’  110 
c-Myc  5’-ACCACCAGCAGCGACTCTGA-3’  5’-TCCAGCAGAAGGTGATCCAGACT-3’  117 
GAPDH  5’-GAAGGTGAAGGTCGGAGTC-3’  5’GAAGATGGTGATGGATTTC-3’  225 
3.7. DNA Content/Cell Cycle Analysis 
Cells were treated with cucurbitacins at various concentrations for 24 h and harvested. The cells 
were washed in 1 mL cold DPBS and fixed with 1 ml 75% ice-cold ethanol. After fixation, the cells 
were stained with 0.5 mL PI/RNase staining solution for 15 min in the dark. The stained cells were 
subjected to DNA content/ cell cycle analysis using a FACSCaliber Flow cytometer system. 
3.8. Statistical Analysis 
Statistical analysis was performed using one-way ANOVA to compare between control and treated 
cells. P values < 0.05 were considered statistically significant. 
4. Conclusions 
Cucurbitacin B from Trichosanthes cucumerina L exerts a growth inhibitory effect in breast cancer 
cells. The most growth inhibition was seen in the ER negative breast cancer cell line SKBR-3. The 
mechanism of cucurbitacin B induced anticancer effects was addressed. In SKBR-3, cucurbitacin B 
blocks the cell cycle at G2/M even at low concentrations. Apoptotic induction was also suggested in 
this cell line according to the increased subG0 fraction after the treatment. Cucurbitacin B inhibits 
telomerase activity in the three breast cancer cell lines and an obvious inhibitory effect was seen in 
SKBR-3 cell rather than ER-positive MCF-7 and T47D cells. Expressions of hTERT and c-Myc were 
also inhibited by cucurbitacin B in these cells, and reduction of c-Myc protein was clearly observed in 
SKBR-3. In summary, anticancer bioactivities of cucurbitacin B are revealed by inhibiting telomerase 
via down regulation of both hTERT and c-Myc expression in breast cancer cells. Int. J. Mol. Sci. 2010, 11                       
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